

Sector: Capital Goods

Result Update

	Change
Reco: Buy	↔
CMP: Rs. 89	
Price Target: Rs. 110	↑
↑ Upgrade ↔ No change ↓ Downgrade	


Company details

Market cap:	Rs. 21,613 cr
52-week high/low:	Rs. 122/56
NSE volume: (No of shares)	151.9 lakh
BSE code:	500049
NSE code:	BEL
Sharekhan code:	BEL
Free float: (No of shares)	119.1 cr

Shareholding (%)

Promoters	51
DII	30
FII	11
Others	8

Price chart



Price performance

(%)	1m	3m	6m	12m
Absolute	28.1	28.5	-11.4	-20.0
Relative to Sensex	18.9	3.2	2.9	-9.3

Sharekhan Research, Bloomberg

Bharat Electronics Limited's (BEL) revenue grew at a robust pace of 49.2% y-o-y to Rs. 5,817 crore, owing to product mix change, healthy execution, and certain backlog of projects being carried over from Q3FY2020 (highest quarterly run rate till now). Strong revenue growth was led by execution of key orders such as i) Part supply of Long Range Surface to Air Missile System, ii) Integrated Air Command and Control System, and iii) Radar Systems and its revenue booking thereof. Input cost pressures led to gross margin contraction of 718 bps y-o-y to 43.2%, however gross profit increased by 27.9% y-o-y to Rs. 2,513 crore owing to healthy revenue increase. Despite higher employee cost, economies of scale resulting in lower other expenses helped EBITDA margin to expand by 112 bps y-o-y to 25.7%, resulting in 56.0% y-o-y growth in EBITDA to Rs. 1,494 crore. Higher operating profit coupled with lower tax incidence of 26.8% as against 32.6% in Q4FY2019 resulted in robust growth of 74.3% y-o-y in PAT to Rs. 1,047 crore (ahead of our expectation of Rs. 782 crore). Order book remained healthy at Rs. 51,970 crore (4x FY2020 revenue) though largely unchanged, while order intake remained weak at Rs. 13,200 crore (down by 44%) during FY2020 but anticipates some pickup in FY2021E owing to expectation of bagging orders such as i) EW Systems, ii) Avionics Package for Light Combat Aircraft, and iii) Smart City Business. Net working capital cycle improved to 19 days as compared to 31 days in FY2019, while higher capex intensity increased gross debt by Rs. 818 crore and net debt by Rs. 626 crore.

Key positives

- Strong operating performance led to robust growth of 49%/56%/74% in revenue/EBITDA/PAT, respectively.
- Healthy revenue visibility owing to healthy order book of Rs. 51,970 crore (4x FY2020 revenue).

Key negatives

- Gross margin impacted adversely by 718 bps to 43.2%
- Quantum of order intake remains weak in FY2020 and expects to be muted in FY2021E.

Our Call

Valuation: Maintain Buy with a revised PT of Rs 110: We expect revenue and earnings to report CAGR of 6.8% and 3.3%, respectively, during FY2020-FY2022E (expect 180 bps margin contraction) owing to current crisis environment led by COVID-19. At the CMP, the stock is trading at 12.8x and 11.9x FY2021E and FY2022E earnings, respectively. Though order intake is expected to be muted in FY2021E, given the strong order book of Rs. 51,970 crore coupled with cash and cash equivalents of Rs. 1400+ crore, we believe the company trades at reasonable valuations. Hence, we retain our Buy rating on the stock with a revised price target (PT) of Rs. 110.

Key Risks

- Heightened competition, delayed execution of orders, and slower pace of fresh order intake might affect revenue growth.
- Higher raw-material prices and increased competitive intensity might put pressure on margins.

Valuation (Consolidated)

Particulars	FY18	FY19	FY20	FY21E	FY22E
Revenue	10,401	12,164	12,968	13,438	14,614
OPM (%)	19.6	23.9	21.2	18.8	18.5
Adjusted PAT	1,432	1,886	1,824	1,691	1,818
% YoY growth	(6.0)	31.8	(3.3)	(7.3)	7.5
Adjusted EPS (Rs.)	5.9	7.7	7.5	6.9	7.5
P/E (x)	15.1	11.5	11.9	12.8	11.9
P/B (x)	2.7	2.3	2.1	2.0	1.8
EV/EBITDA (x)	11.6	8.2	9.0	9.8	9.4
RoNW (%)	18.2	21.9	18.9	16.1	15.9
RoCE (%)	19.4	21.8	18.0	14.3	13.9

Source: Company; Sharekhan estimates

Robust performance in Q4FY2020; beats estimates: BEL's revenue grew at a robust pace of 49.2% y-o-y to Rs. 5,817 crore (ahead of our expectation of Rs. 5,377 crore) owing to healthy execution and certain backlog of projects being carried over from Q3FY2020. Input cost pressures led to gross margin contraction of 718 bps y-o-y to 43.2%; however, gross profit increased by 27.9% y-o-y to Rs. 2,513 crore owing to healthy revenue increase. Despite higher employee cost (up 30%y-o-y), economies of scale led to lower other expense (down 22%) and helped EBITDA margin to expand by 112 bps y-o-y to 25.7% (beating our expectation of 21.9%), resulting in 56.0% y-o-y growth in EBITDA to Rs. 1,494 crore. Higher operating profit coupled with lower tax incidence of 26.8% as against 32.6% in Q4FY2019 resulted in robust growth of 74.3% y-o-y in PAT to Rs. 1,047 crore (ahead of our expectation of Rs. 782 crore).

Order book remains healthy despite slower order intake in FY2020: During FY2020, the company received major orders such as i) Akash Missile System (7 Sqdn), ii) Coastal Surveillance System - Phase II, iii) Upgrade of EW System, iv) Annual Maintenance Contracts, v) Software Defined Radios, and vi) Smart City Business. Hence, total order intake during FY2020 stood at Rs. 13,200 crore. The major orders executed and supplied by the company during FY2020 were i) Part supply of Long-Range Surface to Air Missile System, ii) Smart City and Homeland Security Business, iii) Integrated Air Command and Control System, iv) Radar Systems, and v) Thermal Imaging Cameras. Accordingly, the company registered total turnover of Rs. 12,608 crore during FY2020, wherein export turnover stood at US\$48.59 million. The company's order book as on April 1, 2020, stood at Rs. 51,970 crore and management anticipates key orders such as i) EW Systems, ii) Avionics Package for Light Combat Aircraft, iii) Smart City Business, and iv) Spares/Services to be bagged by the company during FY2021. The company during the year also received order inflow of Rs. 1,200 crore in respect of providing ventilators, which is considered to be an additional source of revenue during FY2021E.

Higher capex intensity increases debt, while net working capital cycle improves: The company's net working cycle improved to 19 days in FY2020 as compared to 31 days in FY2019. Cash flow from operations stood at Rs. 1,166 crore during the year almost similar to FY2019 level, however free cashflow generation during FY2020 stood at Rs. 168 crore as compared to Rs. 429 crore owing to higher capex intensity and increased investments. Gross debt stood at Rs. 3,338 crore, an increase of Rs. 818 crore, while net debt stood at Rs. 1,882 crore, an increase of Rs. 626 crore. Cash and cash equivalents increased by Rs. 192 crore to Rs. 1,457 crore at the end of FY2020.

Focus on sustainable growth plans: The company has been continuously focusing on sustainable growth plans; and in this regards, the company has taken various initiatives such as i) focus on enhancing the R&D capability to introduce futuristic products to bag new businesses, ii) enhance manufacturing capabilities through timely modernisation and expansion of facilities, iii) enter into joint ventures in existing and emerging businesses to enhance business visibility, thereby providing impetus on Make in India initiative, and iv) focus on increasing defense exports to enhance foreign exchange earnings.

Results	Rs cr				
Particulars	Q4FY20	Q4FY19	YoY (%)	Q3FY20	QoQ (%)
Revenue	5,817	3,899	49.2	2,278	155.3
EBITDA	1,494	958	56.0	357	318.8
Other Income	29	36	(20.0)	33	(14.2)
Depreciation	101	99	1.2	92	9.7
Interest Expense	2	11	(83.1)	0	1,508.3
PBT	1,420	883	60.9	298	376.1
Tax Expense	381	288	32.3	86	344.6
PAT	1,047	601	74.3	223	370.1
EPS (Rs.)	4.3	2.5	74.3	0.9	370.1
%			YoY (BPS)		QoQ (BPS)
EBITDA Margin (%)	25.7	24.6	112	15.7	1,003
PAT Margin (%)	18.0	15.4	259	9.8	822

Source: Company; Sharekhan Research

Outlook

Robust order book of Rs. 51,970 crore (4x FY2020 revenue) provides growth visibility: We believe management's strategy of focusing on project management to eliminate lumpiness in quarterly revenue in a fiscal (Q4 is usually the strongest, while Q1 is the weakest) along with targets to increase services revenue share from 8-10% to 15-20% over the next 3-5 years, to mitigate margin volatility, should reap benefits gradually. Management also stated that the government through the 'Make in India' initiative wants to enhance the manufacturing value-added products, which fetches higher margins rather than relying much on outsourcing play, which has lower margin profile. Management expects 10% revenue growth (including ventilators) and margins to be in 20-21% range for FY2021E. Order intake is expected to be muted in FY2021E, considering the ongoing situation led by COVID-19, however it is expected to improve in FY2022E owing to strong focus on increasing defence manufacturing in India and providing a boost to defence exports.

Valuation

Maintain Buy with a revised PT of Rs. 110: We expect revenue and earnings to report CAGR of 6.8% and 3.3%, respectively, during FY2020-FY2022E (expect 180 bps margin contraction) owing to current crisis environment led by COVID-19. At the CMP, the stock is trading at 12.8x and 11.9x its FY2021E and FY2022E earnings, respectively. Though the order intake is expected to be muted in FY2021E, given the strong order book of Rs. 51,970 crore coupled with cash and cash equivalents of Rs. 1,400+ crore, we believe the company trades at reasonable valuations. Hence, we retain our Buy rating on the stock with a revised PT of Rs. 110.

One-year forward P/E (x) band – Trades at reasonable valuations and offers healthy upside



Source: Sharekhan Research

About company

BEL is a PSU having strong manufacturing and R&D capabilities and has robust cost-control measures. The company manufactures electronics, communication, and defence equipment and stands to benefit from enhanced budgetary outlay for strengthening and modernising India's security.

Investment theme

The government's 'Make in India' initiative and rising spends for modernising defence equipment will support earnings growth in the coming years, as BEL is one of the key players with strong research and manufacturing capabilities in the defence space in the country. A robust order book provides strong revenue and earnings visibility. BEL remains our preferred pick in the defence sector on account of its strong manufacturing and R&D base, good cost control, growing indigenisation, and strong balance sheet with improving return ratios.

Key Risks

- ◆ Heightened competition, delayed execution of orders, and slower pace of fresh order intake might affect revenue growth.
- ◆ Higher raw-material prices and increased competitive intensity might put pressure on margins.

Additional Data

Key management personnel

Venkateswara Gowtama Mannava	Executive Chairperson
Amit Sahai	Non-Executive - Non Independent Director
Manjula Jillellamudi	Non-Executive - Non Independent Director
Shikha Gupta	Executive Director
Anandi Ramalingam	Executive Director
Mahesh Venkatachaliah	Executive Director
Vinay Kumar Katyal	Executive Director
Shivakumaran Madaiah Kariyanakatte	Executive Director
Koshy Alexander	Executive Director & Chief Financial Officer
S Sreenivas	Company Secretary & Compliance office

Source: Company Website

Top shareholders

Sr. No.	Holder Name	Holding (%)
1	CPSE ETF	4.89
2	HDFC Midcap Opportunities Fund	4.86
3	Kotak Standard Multicap Fund	3.27
4	Mirae Asset Large Cap Fund	3.26
5	Aditya Birla SunLife Frontline Equity Fund	2.26
6	Bharat 22 ETF	1.82
7	SBI Blue Chip Fund	1.45
8	Life Insurance Corporation of India	2.36

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Sharekhan

by BNP PARIBAS

Know more about our products and services

For Private Circulation only

Disclaimer: This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst further certifies that neither he or its associates or his relatives has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: compliance@sharekhan.com;

For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com

Registered Office: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.